Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731592 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2023.10.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.
JAAD Case Rep
November 2024
Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Advancing therapeutic frontiers in urothelial carcinoma: targeted strategies and clinical implications.
Chin Clin Oncol
December 2024
Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil; Department of Medical Oncology, Hospital de Base do Distrito Federal, Brasília, Brazil.
Urothelial carcinoma poses significant challenges in clinical management due to its aggressive nature and high prevalence. While most diagnoses involve localized disease, advanced urothelial carcinoma (aUC) often leads to short overall survival (OS). Historically, platinum-based chemotherapy has been the primary treatment for aUC, although its efficacy is limited.
View Article and Find Full Text PDFSpatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
BJU Int
January 2025
Department of Urology, University of Duisburg-Essen, Essen, Germany.
Objective: To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC).
Patients And Methods: We assessed the protein expression patterns of Nectin-4 in a spatially organised tissue microarray containing 1386 tissue cores from 314 consecutive patients with UBC who underwent radical cystectomy (2005-2018). Results were correlated with clinicopathological and follow-up data, as well as with different spatial locations (tumour central vs tumour-normal interface and primary tumour vs lymph node [LN] metastases).
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study.
J Geriatr Oncol
January 2025
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Introduction: We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.
Materials And Methods: We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old.
Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.
Future Oncol
January 2025
Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Introduction: The treatment landscape of metastatic urothelial carcinoma (mUC) has evolved with the emergence of programmed cell death protein 1/ligand 1 (PD-1/L1) inhibitors. This study assessed mUC treatment patterns in Europe.
Methods: Data were derived from the Adelphi mUC Disease Specific Programme™ (November 2020 to April 2021), a large, cross-sectional, patient record-based survey of physicians in France, Germany, Italy, Spain, and the United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!